Comparing the B and T cell-mediated immune responses in patients with type 2 diabetes receiving mRNA or inactivated COVID-19 vaccines

Immunity, Cellular 0303 health sciences COVID-19 Vaccines SARS-CoV-2 Immunology COVID-19 Viral Vaccines RC581-607 3. Good health immunological memory response 03 medical and health sciences Diabetes Mellitus, Type 2 Immunoglobulin G Humans RNA, Viral CoronaVac BNT162b2 type 2 diabetes RNA, Messenger Immunologic diseases. Allergy COVID-19 vaccine BNT162 Vaccine
DOI: 10.3389/fimmu.2022.1018393 Publication Date: 2022-10-11T08:30:20Z
ABSTRACT
Acquiring protective immunity through vaccination is essential, especially for patients with type 2 diabetes who are vulnerable adverse clinical outcomes during coronavirus disease 2019 (COVID-19) infection. Type (T2D) associated immune dysfunction. Here, we evaluated the impact of T2D on immunological responses induced by mRNA (BNT162b2) and inactivated (CoronaVac) vaccines, two most commonly used COVID-19 vaccines. The study consisted parts. In Part 1, sera titres IgG antibodies against severe acute respiratory syndrome (SARS-CoV2) alpha receptor binding domain ( RBD), their neutralizing capacity, antigen-specific CD4 + T CD8 cell at 3-6 months after were compared between BNT162b2 (n=60) CoronaVac (n=50) vaccinees or without T2D. was a time-course investigating initial B among (n=16) Our data showed that impaired both cellular humoral CoronaVac. For BNT162b2, displayed reduction in T-helper 1 (Th1) differentiation following first dose. However, this defect rectified second dose resulting comparable levels memory cells, anti-RBD IgG, healthy individuals vaccination. Hence, influences effectiveness vaccines depending platform. findings provide potential mechanism susceptibility developing observed received either just one BNT162b2.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (48)
CITATIONS (19)